3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
NET
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Sarcoma
3
Thyroid Cancer, Papillary
2
Salivary Gland Neoplasms
2
Brain Neoplasms
2
Wilms Tumor
1
Solid Tumors
1
Solid Tumor
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Locally Advanced Solid Tumors
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Cancers With NTRK, ROS1, or ALK Gene Fusions
1
Breast Neoplasms
1
Interventions
pembrolizumab
80
Nivolumab
60
Sunitinib
59
Sorafenib
36
Everolimus
32
pazopanib
30
Axitinib
27
cabozantinib
25
Ipilimumab
24
Bevacizumab
24
atezolizumab
20
belzutifan
19
lenvatinib
16
avelumab
13
Paclitaxel
10
Docetaxel
9
temsirolimus
8
Cyclophosphamide
8
spartalizumab
7
fludarabine
7
Interleukin-2
7
Interferon alpha-2
7
tivozanib
6
durvalumab
6
Cetuximab
6
cemiplimab
5
aldesleukin
5
Ramucirumab
5
CB-839
5
bempegaldesleukin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Renal Cell
×
entrectinib
×
Clear all
NCT02568267
2026-05-27
STARTRK-2
Hoffmann-La Roche
Phase 2
Active not recruiting
534 enrolled
1 FDA